Last reviewed · How we verify
LTB4
At a glance
| Generic name | LTB4 |
|---|---|
| Sponsor | LTB4 Sweden AB |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) (PHASE3)
- Skin IaM: An Exploratory Clinical Trial to Evaluate Changes in Skin Appearance, Colour, and/or Texture Following the Induction of a Local Inflammatory Skin Response (NA)
- Inflammatory Responses in Normal Volunteers and Patients With Abnormal Immune Responses
- The Effect of Levocetirizine on Inflammatory Mediators in Dermatographism
- Comparison Study on Topical Anesthetic Agents (LMX4 and BLT) Prior to Fractional Skin Resurfacing (NA)
- The Effect of a Bifidobacterium and Polydextrose on Body Fat Mass (PHASE2)
- A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis (PHASE2)
- A Pilot Study of LTB4 in HIV-1 Infected Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LTB4 CI brief — competitive landscape report
- LTB4 updates RSS · CI watch RSS
- LTB4 Sweden AB portfolio CI